STOCKWATCH
·
Biotechnology: Pharmaceutical Preparations
AGM/EGMMay 14, 2026, 04:07 PM

Oculis Shareholders Approve 2025 Report, Elect Gregory Perry to Board

AI Summary

Oculis Holding AG announced the results of its 2026 Annual General Meeting, where shareholders approved all agenda items, including the 2025 Annual Report and Financial Statements. The company reported a standalone statutory financial loss of CHF 33,670,000 for 2025, with an accumulated balance sheet loss of CHF 80,247,000 carried forward. Gregory D. Perry was elected to the Board of Directors, and compensation for both non-executive directors and the Executive Committee was approved. Additionally, shareholders approved changes to the capital structure, including a capital band and conditional share capital for employees.

Key Highlights

  • Shareholders approved all agenda items at the 2026 Annual General Meeting.
  • Approved the 2025 Annual Report and Financial Statements.
  • Company incurred a standalone statutory financial loss of CHF 33,670,000 for 2025.
  • Accumulated balance sheet loss of CHF 80,247,000 carried forward.
  • Gregory D. Perry was elected as a new member of the Board of Directors.
  • Approved maximum fixed compensation for non-executive directors: $572,000 until 2027 AGM.
  • Approved maximum equity-based compensation for Executive Committee until 2027: $18,000,000.
  • Approved a capital band of 31,020,888 registered shares and related amendments.
  • Total registered shares increased to 62,041,776, with 5,750,400 new shares issued as treasury shares.
  • Company will own 9.15% of its registered shares as treasury shares.
OCS
Biotechnology: Pharmaceutical Preparations
Oculis Holding AG

Price Impact